Isoform-selective histone deacetylase inhibitors
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Histone deacetylase (HDAC) proteins are transcription regulators linked to cancer. As a result, multiple small molecule HDAC inhibitors are in various phases of clinical trials as anti-cancer drugs. The majority of HDAC inhibitors non-selectively influence the activities of eleven human HDAC isoforms, which are divided into distinct classes. This tutorial review focuses on the recent progress toward the identification of class-selective and isoform-selective HDAC inhibitors. The emerging trends suggest that subtle differences in the active sites of the HDAC isoforms can be exploited to dictate selectivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone deacetylases (HDACs) are epigenetic regulators that modulate gene expression by removing acetyl groups from lysine residues on proteins, affecting processes like cell proliferation, differentiation, and development.504,505”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [504]
Citations
Cites
Epigenetic programming by maternal behavior
Weaver, I. C. G., Cervoni, N., Champagne, F. A., D'Alessio, A. C., Sharma, S., Seckl, J. R., Dymov, S., Szyf, M., & Meaney, M. J. (2004) · Nature Neuroscience · doi:10.1038/nn1276 · Cited by 6,177
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
(2002) · PubMed · Cited by 732
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710
Research works printed but not linked: 1
- Furumai, 2002, Cancer Res., 62, 4916
Cited by
Items 301–396 of 396
A Tale of Two Epiphenomena: The Complex Interplay of Epigenetics and Epilepsy
Beth, S. T., & Jane, A. V. A. (2011) · InTech eBooks · doi:10.5772/24529 · Cited by 4
Caboche, J., Roze, E. F., Brami‐Cherrier, K., & Bétuing, S. (2010) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-374767-9.00030-5 · Cited by 1
Histone Deacetylase Inhibitors (HDACIs): Untapped Therapeutic Potential in Cancer Treatment
Dario Tomas Duc, P. (2014) · Journal of Bioequivalence & Bioavailability · doi:10.4172/jbb.10000e53 · Cited by 1
Amodio, N., Morelli, E., Barone, A., & Tassone, P. (2016) · Springer eBooks · doi:10.1007/978-3-319-31254-5_3 · Cited by 1
Ganai, S. A. (2019) · Springer eBooks · doi:10.1007/978-981-13-8019-8_8 · Cited by 1
Current Challenges with HDAC Inhibitor-Based Therapeutic Intervention Against Neurological Maladies
Ganai, S. A. (2019) · Springer eBooks · doi:10.1007/978-981-13-8019-8_7 · Cited by 1
Khathayer, F. H. (2024) · Maǧallaẗ ǧāmiʿaẗ al-Sulṭān Qābūs li-l-ʿulūm/Sultan Qaboos University journal for science · doi:10.53539/squjs.vol29isspp1-14 · Cited by 1
Hsu, K., Huang, Y., Chu, J.-C., Huang, Y.-W., Hu, J., Lin, T. E., Yen, S., Weng, J.-R., & Huang, W.-J. (2024) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2024.2406025 · Cited by 1
Dewaker, V., Srivastava, P. N., Debnath, U., Srivastava, A. K., & Prabhakar, Y. S. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110262 · Cited by 2
In silco studies on modified hydroxamic acid and valporic acid as potential inhibitors for HDAC2
Kandakatla, N., Rathaur, S., Sahoo, S. S., & Ramakrishnan, G. (2013) · Bangladesh Journal of Pharmacology · doi:10.3329/bjp.v8i3.15433 · Cited by 1
Epigenetic Diabetic Vascular Complications
Amiri, A. A., & Amiri, A. A. (2016) · Journal of Pediatrics Review · doi:10.17795/jpr-3375 · Cited by 1
Ganai, S. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-8179-3_11 · Cited by 2
Epigenetics and Type 2 Diabetes
Ling, C., Rönn, T., & Nitert, M. D. (2011) · Springer eBooks · doi:10.1007/978-1-84882-644-1_9 · Cited by 1
The Role of Histone Deacetylases in Cytokine Regulation in Human Gestational Tissues
Munro, S. K. (2013) · ResearchSpace (University of Auckland) · Cited by 2
Hanessian, S. (2014) · Methods and principles in medicinal chemistry · doi:10.1002/9783527676545.ch16
Synthesis and Biological Evaluation of Histone Deacetylase Inhibitor Largazole and Analogs
Bhansali, P. R. (2011) · OhioLink ETD Center (Ohio Library and Information Network)
Histone Deacetylase Inhibitors: A Brief Overview Of Their Role And Medicinal Chemistry
Angibaud, P. R., Emelen, K. V., & Arts, J. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc213
Lozada, E., & Santiago, L. (2011) · UKnowledge (University of Kentucky)
Elucidation of the Histone Deacetylase 6 Pharmacophore
Kalin, J. H. (2012) · Figshare
Evaluation of inhibitors of histone deacetylases as potential neurotrophic agents
Shukla, S., Muhammad, I., Walker, L., & Tekwani, B. (2014) · Planta Medica · doi:10.1055/s-0034-1382607
Evaluation of Photoreactive and Phenothiazine-based HDAC Inhibitors
Madriaga, A. (2014) · Figshare
Reprogramming to Pluripotency Using Small Molecule Compounds
Greenberg, B. E. (2015) · doi:10.21007/etd.cghs.2015.0117
The Transcription Factor ERG is a Gatekeeper of Endothelial Cell Homeostasis
Dryden, N. H. (2012) · Spiral (Imperial College London) · doi:10.25560/9798
Molecular mechanisms affecting estrogen receptor levels in breast cancer
Okat, Z. (2018) · Journal of Surgery and Medicine · doi:10.28982/josam.412314
Structural, functional and inhibition studies of human histone deacetylase 7
Desravines, D. C. (2010) · HAL
Target Identification of HDAC8 Isoform for the Treatment of Cancer
Umamaheswari, A., Puratchikody, A., & Balasubramaniyan, S. (2018) · Advances in medical technologies and clinical practice book series · doi:10.4018/978-1-5225-7326-5.ch007
Epigenomics of Diabetes Mellitus
Dimova, I. I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814513-5.00012-x
Ravikumar, V., Anusha, C., & Chidambaram, R. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00008-5
ChemInform Abstract: Isoform‐Selective Histone Deacetylase Inhibitors
Bieliauskas, A. V., & Pflum, M. K. H. (2008) · ChemInform · doi:10.1002/chin.200840275
Self-citationDias, P. G. G. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/3xwd-bf33
Gerling, I. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.9764956.10457054
Epigenetic therapy in lung cancer
Conroy, M. R., O’Connor, Á., Bailey‐Whyte, M., & Dowling, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91367-6.00004-0
Histone deacetylases and other epigenetic targets
Carta, F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823974-2.00037-1 · Cited by 1
Study of substitution reaction on ring a of estradiol
Boonyaratsewee, C. (2018) · Chula Digiverse · doi:10.58837/chula.the.2018.93
Ye, X., Mao, N., Xu, Y., Yao, X., Gao, Y., Hui, Z., Che, H., Wang, C., Hu, S., & Zhang, H. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4871762
Valproic Acid Inhibits RhoA-Mediated Vascular Smooth Muscle Cell Contraction
Park, J.-K., Kim, S. M., Lee, H. J., Hwang, Y., & Cho, D. (2025) · Journal of Korean Medical Science · doi:10.3346/jkms.2025.40.e199
Rizwan, A., Aqeel, A., Choudhary, F., Nizam, A., Khan, A., & Farooqi, H. (2025) · Nutrition · doi:10.1016/j.nut.2025.112955 · Cited by 2
Pai, P., Das, I., Reddy, Y., Venkidesh, B. S., Bhandari, P., Madalageri, M., Sadashivanavar, V., Pai, K. S. R., Rao, P., Oruganti, S., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02194-7 · Cited by 4
Repositioning HDAC Inhibitors for Glioma Treatment: Synthesis and Biological Evaluation
Furtado, L. C., Waitman, K. B., Silva, N. A. T. F., Gouvea, L. M., Kronenberger, T., Toledo, M. F. Z. J., Ferreira, E. G., Machado‐Neto, J. A., Kruyt, F. A. E., Parise‐Filho, R., et al. (2026) · ACS Omega · doi:10.1021/acsomega.5c11083 · Cited by 2
Ahmadi, Y. E. (2020) · theses.fr (ABES) · doi:10.70675/cd8f08aezd8ecz4711zb43czd35ef03dfd1b
Polyphenols as epigenetic modulators: Curcumin, resveratrol, and quercetin
Kalra, M., & Kumar, U. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45146-1.00009-6
Thangavelu, T., Arockiasamy, P., Pandian, U., & Thirumalai, S. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7620313
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
BindingDB Entry 50022489: Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity.
BindingDB (2025) · UC San Diego · doi:10.7270/q2v410zp
BindingDB (2010) · UC San Diego · doi:10.7270/q2nz87qh
BindingDB Entry 50017631: Discovery of HDAC6-Selective Inhibitor NN-390 with
BindingDB (2023) · UC San Diego · doi:10.7270/q2qv3rkm
BindingDB Entry 50044935: Aurones as histone deacetylase inhibitors: identification of key features.
BindingDB (2016) · UC San Diego · doi:10.7270/q2x3502t
BindingDB Entry 50007194: Highly fluorescent and HDAC6 selective scriptaid analogues.
BindingDB (2021) · UC San Diego · doi:10.7270/q2jq14bb
BindingDB Entry 50042978: Discovery of the first histone deacetylase 6/8 dual inhibitors.
BindingDB (2014) · UC San Diego · doi:10.7270/q27h1m0s
BindingDB (2010) · UC San Diego · doi:10.7270/q2pv6k7w
BindingDB Entry 50043006: A cyclodextrin-capped histone deacetylase inhibitor.
BindingDB (2014) · UC San Diego · doi:10.7270/q2mk6f89
BindingDB (2015) · UC San Diego · doi:10.7270/q2hh6mm7
BindingDB Entry 50033616: A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.
BindingDB (2012) · UC San Diego · doi:10.7270/q20p10ct
BindingDB Entry 50022176: Advances in dual-targeting inhibitors of HDAC6 for cancer treatment.
BindingDB (2025) · UC San Diego · doi:10.7270/q24x5dg9
BindingDB Entry 50032244: Design and synthesis of novel isoxazole-based HDAC inhibitors.
BindingDB (2011) · UC San Diego · doi:10.7270/q20z73gf
BindingDB Entry 50033283: Discovery of histone deacetylase 8 selective inhibitors.
BindingDB (2011) · UC San Diego · doi:10.7270/q2zc835m
BindingDB (2024) · UC San Diego · doi:10.7270/q2p55sv5
BindingDB Entry 50000223: Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
BindingDB (2019) · UC San Diego · doi:10.7270/q2n018zr
BindingDB (2014) · UC San Diego · doi:10.7270/q29g5p7j
BindingDB Entry 50027905: Sulfamides as novel histone deacetylase inhibitors.
BindingDB (2010) · UC San Diego · doi:10.7270/q2416wxb
BindingDB (2011) · UC San Diego · doi:10.7270/q28g8kzj
Conformational Variability: Implications for Biomolecular Activity and in Drug Design
Bhattacharyya, M. (2012) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Acute kidney injury in zebrafish larvae as a regeneration model for drug discovery
Skvarca, L. B. (2015) · D-Scholarship@Pitt (University of Pittsburgh)
Metadata
- Authors
- Bieliauskas, A. V., & Pflum, M. K. H.
- Affiliations
- Wayne State University (US)
- Corresponding author
- Pflum, Mary Kay H.
- ORCID
- Pflum, Mary Kay H.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2008
- Volume
- 37
- Issue
- 7
- Pages
- 1402
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- PMC
- PMC2593472
- OpenAlex
- W2124258829
- Cited by
- 350
- References
- 59
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 15 · 2023: 16 · 2022: 10 · 2021: 12 · 2020: 21 · 2019: 20 · 2018: 19 · 2017: 16 · 2016: 21 · 2015: 21 · 2014: 27 · 2013: 22 · 2012: 22
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of General Medical Sciences (GM 067657, R01GM067657)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- histone deacetylase inhibitors, HDAC isoforms, isoform selectivity, cancer therapy, small molecule inhibitors, transcriptional regulation
- MeSH terms
- Vorinostat, Antineoplastic Agents, Binding Sites, Enzyme Inhibitors, Histone Deacetylases, Humans, Hydroxamic Acids, Tumor Cells, Cultured, Drug Design, Protein Isoforms, Cell Proliferation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.